Literature DB >> 6771083

Management of infants with Robin anomaly.

M B Lewis, H M Pashayan.   

Abstract

Congenital micrognathia and secondary glossoptosis, with or without cleft palate, constitute the Robin anomaly. Neonates with this condition are usually at great risk for life-threatening respiratory and feeding problems. The approach to the management of infants with this condition has included, in order of increasing complexity, positioning of the patient, surgical tongue-lip adhesion and tracheostomy. Because of dissatisfaction with the effectiveness of surgical tongue-lip adhesion, and a desire to avoid performing a tracheostomy, a trial of intense non-surgical management was instituted. Ten consecutive patients admitted to the Boston Floating Hospital with Robin anomaly were treated successfully by positioning, without requiring tongue-lip adhesion or tracheostomy. Medical management procedures are outlined and discussed.

Entities:  

Mesh:

Year:  1980        PMID: 6771083     DOI: 10.1177/000992288001900802

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  3 in total

Review 1.  Development of oral-motor skills in the neurologically impaired child receiving non-oral feedings.

Authors:  S E Morris
Journal:  Dysphagia       Date:  1989       Impact factor: 3.438

2.  Pierre Robin sequence and Treacher Collins hypoplastic mandible comparison using three-dimensional morphometric analysis.

Authors:  Michael T Chung; Benjamin Levi; Jeong S Hyun; David D Lo; Daniel T Montoro; Jeffrey Lisiecki; James P Bradley; Steven R Buchman; Michael T Longaker; Derrick C Wan
Journal:  J Craniofac Surg       Date:  2012-11       Impact factor: 1.046

3.  The Effect of Timing of Mandibular Distraction Osteogenesis on Weight Velocity in Infants Affected by Severe Robin Sequence.

Authors:  Zhe Mao; Ricardo Battaglino; Jiawei Zhou; Yingqiu Cui; Mayank Shrivastava; Gabriel Tian; Faezeh Sahebdel; Liang Ye
Journal:  Children (Basel)       Date:  2022-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.